Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

A two-part phase I study to establish and compare the safety and local tolerability of two nasal formulations of XF-73 for decolonization of Staphylococcus aureus: A previously investigated 0.5 mg/g viscosified gel formulation versus a modified formulation.

Yendewa GA, Griffiss JM, Jacobs MR, Fulton SA, O'Riordan MA, Gray WA, Proskin HM, Winkle P, Salata RA.

J Glob Antimicrob Resist. 2019 Oct 7. pii: S2213-7165(19)30250-4. doi: 10.1016/j.jgar.2019.09.017. [Epub ahead of print]

PMID:
31600598
2.

Development and validation of an LC-MS/MS method for the simultaneous determination of bedaquiline and rifabutin in human plasma.

Gray WA, Waldorf B, Rao MG, Stiles BL, Griffiss JM, Salata RA, Blumer JL.

J Pharm Biomed Anal. 2019 Nov 30;176:112775. doi: 10.1016/j.jpba.2019.07.023. Epub 2019 Aug 16.

PMID:
31446299
3.

How to Identify Exposed Women Who Are Infected with Neisseria gonorrhoeae.

McLaughlin SE, Griffiss JM.

Methods Mol Biol. 2019;1997:29-36. doi: 10.1007/978-1-4939-9496-0_2.

PMID:
31119615
4.

Effects of Rifamycin Coadministration on Bedaquiline Desmethylation in Healthy Adult Volunteers.

Healan AM, Salata RA, Griffiss JM, Proskin HM, O'Riordan MA, Gray WA, Blumer JL.

Clin Pharmacol Drug Dev. 2019 May;8(4):436-442. doi: 10.1002/cpdd.639. Epub 2018 Nov 30.

PMID:
30500116
5.

Risk of Gonococcal Infection During Vaginal Exposure is Associated With High Vaginal pH and Active Menstruation.

McLaughlin SE, Ghanem KG, Zenilman JM, Griffiss JM.

Sex Transm Dis. 2019 Feb;46(2):86-90. doi: 10.1097/OLQ.0000000000000926.

6.

Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial.

Wallis RS, Good CE, O'Riordan MA, Blumer JL, Jacobs MR, Griffiss JM, Healan A, Salata RA.

PLoS One. 2018 May 2;13(5):e0196756. doi: 10.1371/journal.pone.0196756. eCollection 2018.

7.

A Phase 1 Pharmacokinetic and Safety Study of Extended-Duration, High-dose Cefixime for Cephalosporin-resistant Neisseria gonorrhoeae in the Pharynx.

Barbee LA, Nayak SU, Blumer JL, OʼRiordan MA, Gray W, Zenilman JM, Golden MR, Griffiss JM.

Sex Transm Dis. 2018 Oct;45(10):677-683. doi: 10.1097/OLQ.0000000000000844.

PMID:
29624558
8.

Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers.

Healan AM, Griffiss JM, Proskin HM, O'Riordan MA, Gray WA, Salata RA, Blumer JL.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e00855-17. doi: 10.1128/AAC.00855-17. Print 2018 Jan.

9.

Safety, Tolerability, Systemic Exposure, and Metabolism of CRS3123, a Methionyl-tRNA Synthetase Inhibitor Developed for Treatment of Clostridium difficile, in a Phase 1 Study.

Nayak SU, Griffiss JM, Blumer J, O'Riordan MA, Gray W, McKenzie R, Jurao RA, An AT, Le M, Bell SJ, Ochsner UA, Jarvis TC, Janjic N, Zenilman JM.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e02760-16. doi: 10.1128/AAC.02760-16. Print 2017 Aug.

10.

Response.

Berry SM, Petzold EA, Dull P, Thielman NM, Cunningham CK, McClain MT, Hoover DL, Russell J, Griffiss JM, Woods CW.

Clin Trials. 2016 Oct;13(5):568-9. doi: 10.1177/1740774516654446. Epub 2016 Jun 30. No abstract available.

PMID:
27365016
11.

A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic response.

Berry SM, Petzold EA, Dull P, Thielman NM, Cunningham CK, Corey GR, McClain MT, Hoover DL, Russell J, Griffiss JM, Woods CW.

Clin Trials. 2016 Feb;13(1):22-30. doi: 10.1177/1740774515621721. Epub 2016 Jan 14.

12.

Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin A.

Nayak SU, Griffiss JM, McKenzie R, Fuchs EJ, Jurao RA, An AT, Ahene A, Tomic M, Hendrix CW, Zenilman JM.

Antimicrob Agents Chemother. 2014 Sep;58(9):5047-53. doi: 10.1128/AAC.02830-14. Epub 2014 Jun 9.

13.

Stability of colistimethate sodium in aqueous solution.

Healan AM, Gray W, Fuchs EJ, Griffiss JM, Salata RA, Blumer J.

Antimicrob Agents Chemother. 2012 Dec;56(12):6432-3. doi: 10.1128/AAC.01079-12. Epub 2012 Oct 15.

14.

Lack of lipid A pyrophosphorylation and functional lptA reduces inflammation by Neisseria commensals.

John CM, Liu M, Phillips NJ, Yang Z, Funk CR, Zimmerman LI, Griffiss JM, Stein DC, Jarvis GA.

Infect Immun. 2012 Nov;80(11):4014-26. doi: 10.1128/IAI.00506-12. Epub 2012 Sep 4.

15.

Urethral exudates of men with Neisseria gonorrhoeae infections select a restricted lipooligosaccharide phenotype during transmission.

McLaughlin SE, Cheng H, Ghanem KG, Yang Z, Melendez J, Zenilman J, Griffiss JM.

J Infect Dis. 2012 Oct;206(8):1227-32. Epub 2012 Aug 16.

16.

The association between body mass index and severe biliary infections: a multivariate analysis.

Stewart L, Griffiss JM, Jarvis GA, Way LW.

Am J Surg. 2012 Nov;204(5):574-9. doi: 10.1016/j.amjsurg.2012.07.002. Epub 2012 Aug 11.

PMID:
22892201
17.

Human lipooligosaccharide IGG that prevents endemic meningococcal disease recognizes an internal lacto-N-neotetraose structure.

Cheng H, Yang Z, Estabrook MM, John CM, Jarvis GA, McLaughlin S, Griffiss JM.

J Biol Chem. 2011 Dec 23;286(51):43622-33. doi: 10.1074/jbc.M111.291583. Epub 2011 Oct 25.

18.

Neisseria gonorrhoeae-induced transactivation of EGFR enhances gonococcal invasion.

Swanson KV, Griffiss JM, Edwards VL, Stein DC, Song W.

Cell Microbiol. 2011 Jul;13(7):1078-90. doi: 10.1111/j.1462-5822.2011.01603.x. Epub 2011 May 30.

19.

Structural characterization of an oligosaccharide made by Neisseria sicca.

O'Connor ET, Zhou H, Bullock K, Swanson KV, Griffiss JM, Reinhold VN, Miller CJ, Stein DC.

J Bacteriol. 2009 May;191(10):3311-20. doi: 10.1128/JB.01433-08. Epub 2009 Mar 6.

20.

Structural requirements for monoclonal antibody 2-1-L8 recognition of neisserial lipooligosaccharides.

O'Connor ET, Swanson KV, Cheng H, Fluss K, Griffiss JM, Stein DC.

Hybridoma (Larchmt). 2008 Apr;27(2):71-9.

PMID:
18642671
21.
22.

Gallstones containing bacteria are biofilms: bacterial slime production and ability to form pigment solids determines infection severity and bacteremia.

Stewart L, Griffiss JM, Jarvis GA, Way LW.

J Gastrointest Surg. 2007 Aug;11(8):977-83; discussion 983-4.

PMID:
17546479
23.

Biochemical analysis of Lpt3, a protein responsible for phosphoethanolamine addition to lipooligosaccharide of pathogenic Neisseria.

O'Connor ET, Piekarowicz A, Swanson KV, Griffiss JM, Stein DC.

J Bacteriol. 2006 Feb;188(3):1039-48.

25.

Spectrum of gallstone disease in the veterans population.

Stewart L, Griffiss JM, Way LW.

Am J Surg. 2005 Nov;190(5):746-51.

PMID:
16226952
26.

Binding of the Streptococcus gordonii surface glycoproteins GspB and Hsa to specific carbohydrate structures on platelet membrane glycoprotein Ibalpha.

Takamatsu D, Bensing BA, Cheng H, Jarvis GA, Siboo IR, López JA, Griffiss JM, Sullam PM.

Mol Microbiol. 2005 Oct;58(2):380-92.

27.

Cognitive behavioral therapy and aerobic exercise for Gulf War veterans' illnesses: a randomized controlled trial.

Donta ST, Clauw DJ, Engel CC Jr, Guarino P, Peduzzi P, Williams DA, Skinner JS, Barkhuizen A, Taylor T, Kazis LE, Sogg S, Hunt SC, Dougherty CM, Richardson RD, Kunkel C, Rodriguez W, Alicea E, Chiliade P, Ryan M, Gray GC, Lutwick L, Norwood D, Smith S, Everson M, Blackburn W, Martin W, Griffiss JM, Cooper R, Renner E, Schmitt J, McMurtry C, Thakore M, Mori D, Kerns R, Park M, Pullman-Mooar S, Bernstein J, Hershberger P, Salisbury DC, Feussner JR; VA Cooperative Study #470 Study Group.

JAMA. 2003 Mar 19;289(11):1396-404.

PMID:
12636462
28.

Pathogenesis of pigment gallstones in Western societies: the central role of bacteria.

Stewart L, Oesterle AL, Erdan I, Griffiss JM, Way LW.

J Gastrointest Surg. 2002 Nov-Dec;6(6):891-903; discussion 903-4.

PMID:
12504229
29.

Galectin-3 binds lactosaminylated lipooligosaccharides from Neisseria gonorrhoeae and is selectively expressed by mucosal epithelial cells that are infected.

John CM, Jarvis GA, Swanson KV, Leffler H, Cooper MD, Huflejt ME, Griffiss JM.

Cell Microbiol. 2002 Oct;4(10):649-62.

PMID:
12366402
30.

Gram-negative bacteria killed by complement are associated with more severe biliary infections and produce more tumor necrosis factor-alpha in sera.

Stewart L, Oesterle AL, Griffiss JM, Jarvis GA, Aagaard B, Way LW.

Surgery. 2002 Aug;132(2):408-14.

PMID:
12219042
31.

Experimental gonococcal urethritis and reinfection with homologous gonococci in male volunteers.

Schmidt KA, Schneider H, Lindstrom JA, Boslego JW, Warren RA, Van de Verg L, Deal CD, McClain JB, Griffiss JM.

Sex Transm Dis. 2001 Oct;28(10):555-64.

PMID:
11689753
32.

CEACAM is not necessary for Neisseria gonorrhoeae to adhere to and invade female genital epithelial cells.

Swanson KV, Jarvis GA, Brooks GF, Barham BJ, Cooper MD, Griffiss JM.

Cell Microbiol. 2001 Oct;3(10):681-91.

PMID:
11580753
33.

Pigment gallstone pathogenesis: slime production by biliary bacteria is more important than beta-glucuronidase production.

Stewart L, Ponce R, Oesterle AL, Griffiss JM, Way LW.

J Gastrointest Surg. 2000 Sep-Oct;4(5):547-53.

PMID:
11077333
34.
35.
37.
38.
39.

Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group.

Donta ST, Peduzzi P, Cross AS, Sadoff J, Haakenson C, Cryz SJ Jr, Kauffman C, Bradley S, Gafford G, Elliston D, Beam TR Jr, John JF Jr, Ribner B, Cantey R, Welsh CH, Ellison RT 3rd, Young EJ, Hamill RJ, Leaf H, Schein RM, Mulligan M, Johnson C, Abrutyn E, Griffiss JM, Slagle D, et al.

J Infect Dis. 1996 Sep;174(3):537-43.

PMID:
8769611
40.

Bacterial enzymes can add galactose alpha 1,3 to human erythrocytes and creates a senescence-associated epitope.

Hamadeh RM, Jarvis GA, Zhou P, Cotleur AC, Griffiss JM.

Infect Immun. 1996 Feb;64(2):528-34.

41.

Anti-Gal binds to pili of Neisseria meningitidis: the immunoglobulin A isotype blocks complement-mediated killing.

Hamadeh RM, Estabrook MM, Zhou P, Jarvis GA, Griffiss JM.

Infect Immun. 1995 Dec;63(12):4900-6.

42.

Anti-alpha-galactosyl immunoglobulin A (IgA), IgG, and IgM in human secretions.

Hamadeh RM, Galili U, Zhou P, Griffiss JM.

Clin Diagn Lab Immunol. 1995 Mar;2(2):125-31.

44.
45.

Differences in outer membrane characteristics between gallstone-associated bacteria and normal bacterial flora.

Wetter LA, Hamadeh RM, Griffiss JM, Oesterle A, Aagaard B, Way LW.

Lancet. 1994 Feb 19;343(8895):444-8.

PMID:
7905954
46.

Isolation and characterization of lipopolysaccharides, lipooligosaccharides, and lipid A.

Apicella MA, Griffiss JM, Schneider H.

Methods Enzymol. 1994;235:242-52. Review. No abstract available.

PMID:
8057898
47.

HLA expression by benign and malignant prostatic epithelium: augmentation by interferon-gamma.

Blumenfeld W, Ye JQ, Dahiya R, Griffiss JM, Narayan P.

J Urol. 1993 Oct;150(4):1289-92.

PMID:
7690428
48.

Does ozone alleviate AIDS diarrhea?

Carpendale MT, Freeberg J, Griffiss JM.

J Clin Gastroenterol. 1993 Sep;17(2):142-5.

PMID:
8409316
49.

Neuraminic acid is alpha 2-->3 linked in the lipooligosaccharide of Neisseria meningitidis serogroup B strain 6275.

Yamasaki R, Griffiss JM, Quinn KP, Mandrell RE.

J Bacteriol. 1993 Jul;175(14):4565-8.

Supplemental Content

Loading ...
Support Center